Search Within

Joachim Yahalom

  1. "Ana Alarcon Tomas"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (4)
Groups
  1. Bone Marrow Transplant (15)
  2. CTCR Scholars (15)
  3. Center for Hematologic Malignancies (15)
  4. Department of Medicine (15)
  5. Hematologic Malignancies, Division of (15)
  6. Lymphoma (15)

More Groups

People
  1. Ana Alarcon Tomas (15)
  2. Brandon Imber (15)
  3. Gunjan Shah (15)
  4. Maria Palomba (15)
  5. Michael Scordo (15)
  6. Miguel-Angel Perales (15)

More People

Years
  1. 2024 (2)
  2. 2023 (6)
  3. 2022 (3)
  4. 2021 (3)
  5. 2020 (1)
Publications
  1. Blood (6)
  2. Hematological Oncology (2)
  3. International Journal of Radiation Oncology, Biology, Physics (2)
  4. Transplantation and Cellular Therapy (2)
  5. Blood Advances (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. Elsevier Inc. (4)
  3. Wiley Blackwell (2)
  4. American Association for Cancer Research (1)
  5. Nature Publishing Group (1)

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E.; Wijetunga, N. A.; Palomba, M. L.; Tomas, A. A.; Shouval, R.; Batlevi, C. W.; Dahi, P. B.; Giralt, S. A.; Lin, R. J.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study
    Meeting Abstract

    Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas
    Meeting Abstract

    Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
    Blood (2020)

    Fulltext@MSK | Save